0000950170-22-001386.txt : 20220217 0000950170-22-001386.hdr.sgml : 20220217 20220217065205 ACCESSION NUMBER: 0000950170-22-001386 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220217 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220217 DATE AS OF CHANGE: 20220217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDNAX, INC. CENTRAL INDEX KEY: 0000893949 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 263667538 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12111 FILM NUMBER: 22645587 BUSINESS ADDRESS: STREET 1: 1301 CONCORD TERRACE CITY: SUNRISE STATE: FL ZIP: 33323 BUSINESS PHONE: 9543840175 MAIL ADDRESS: STREET 1: 1301 CONCORD TERRACE CITY: SUNRISE STATE: FL ZIP: 33323 FORMER COMPANY: FORMER CONFORMED NAME: PEDIATRIX MEDICAL GROUP INC DATE OF NAME CHANGE: 19950801 8-K 1 md-20220217.htm 8-K 8-K
0000893949false00008939492022-02-172022-02-17

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 17, 2022

 

 

Mednax, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Florida

001-12111

26-3667538

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1301 Concord Terrace

 

Sunrise, Florida

 

33323

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 954 384-0175

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $.01 per share

 

MD

 

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

On February 17, 2022, Mednax, Inc., a Florida corporation (the “Company”), issued a press release announcing the results of its operations for the three months and twelve months ended December 31, 2021 (the “Fourth Quarter Release”). A copy of the Fourth Quarter Release is attached hereto as Exhibit 99.1 and is hereby incorporated in this Current Report by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” with the Securities and Exchange Commission nor incorporated by reference in any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit Index

 

99.1— Press Release of Mednax, Inc. dated February 17, 2022.

104 — Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

MEDNAX, INC.

 

 

 

 

Date:

February 17, 2022

By:

/s/ C. Marc Richards

 

 

 

C. Marc Richards
Chief Financial Officer

 

 EX-99.1 2 md-ex99_1.htm EX-99.1 EX-99.1

 

 

img163251054_0.jpg 

 

 

FOR MORE INFORMATION:

Charles Lynch

Senior Vice President, Finance and Strategy

954-384-0175, x 5692

charles_lynch@mednax.com

 

FOR IMMEDIATE RELEASE

 

Mednax Reports Fourth Quarter Results

 

FORT LAUDERDALE, Fla., February 17, 2022 - Mednax, Inc. (NYSE: MD), and its affiliated practices operating as Pediatrix® Medical Group, the nation’s leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.47 per share for the three months ended December 31, 2021. On a non-GAAP basis, Mednax reported Adjusted EPS from continuing operations of $0.52.

 

For the 2021 fourth quarter, Mednax reported the following results from continuing operations:

•
Net revenue of $499 million;
•
Income from continuing operations of $68 million; and
•
Adjusted EBITDA of $81 million.

 

“Our fourth quarter results mark the end of a solid year, thanks to our focus on women’s, newborns’, and children’s health,” said Mark S. Ordan, Chief Executive Officer of Mednax. “We strengthened our support for our affiliated practices, enhanced our efficiency, and made important investments to position ourselves for growth in pediatric primary and urgent care. Thus far in 2022, we have accelerated those investments, including our entry in Florida. Finally, we believe our recently completed refinancing transactions provide us with optimal financial flexibility and significantly reduced ongoing interest expense.”

 

Operating Results from Continuing Operations – Three Months Ended December 31, 2021

 

Mednax’s net revenue for the three months ended December 31, 2021 was $498.5 million, compared to $416.6 million for the prior-year period. Mednax’s overall same-unit revenue increased by 17.6 percent, modestly complemented by net acquisition activity.

 

Same-unit revenue from net reimbursement-related factors increased by 11.3 percent for the 2021 fourth quarter as compared to the prior-year period. The net increase primarily reflects funds received under the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act; an approximately 230 basis point increase in the percentage of services reimbursed by commercial

 

 

and other non-government payors; increases in contract and administrative fees; and modest improvements in managed care contracting. During the 2021 fourth quarter, the Company recorded $18.4 million of miscellaneous revenue from the provider relief fund established by the CARES Act compared to $2.0 million in the prior year, which increased the Company’s same-unit revenue from net reimbursement-related factors by 4.1 percent.

 

Same-unit revenue attributable to patient volume increased by 6.3 percent for the 2021 fourth quarter as compared to the prior-year period. Shown below are year-over-year percentage changes in certain same-unit volume statistics for the three months and the year ended December 31, 2021. (Note: figures in the below table reflect contributions only to net patient service revenue and exclude other contributions to total same-unit revenue, including contract and administrative fees.)

 



 

Three Months Ended
December 31, 2021

 

Twelve Months Ended
December 31, 2021

Hospital-based patient services

 

8.7%

 

5.2%

Office-based patient services

 

6.4%

 

9.8%

 

 

 

 

 

Neonatology services
(within hospital-based services):

 

 

 

 

Total births

 

5.0%

 

2.5%

Neonatal intensive care unit (NICU) days

 

5.6%

 

3.4%

 

For the 2021 fourth quarter, practice salaries and benefits expense was $332.7 million, compared to $284.8 million for the prior-year period. This increase primarily reflects increases in variable incentive compensation, based on practice-level revenue and other financial results during the quarter, as well as acquisitions completed over the past year.

 

For the 2021 fourth quarter, general and administrative expenses were $59.0 million, as compared to $54.7 million for the prior-year period.

 

For the fourth quarter of 2021, transformational and restructuring related expenses totaled $3.1 million, compared to $13.0 million for the fourth quarter of 2020. The expense recorded during the fourth quarter of 2021 predominantly related to contract termination fees, including as part of the Company’s transition to a third-party revenue cycle management provider.

 

Adjusted EBITDA from continuing operations, which is defined as earnings from continuing operations before interest, taxes, depreciation and amortization, and transformational and restructuring related expenses, was $81.0 million for the 2021 fourth quarter, compared to $58.3 million for the prior-year period. Funds received from the provider relief fund established by the CARES Act favorably impacted Adjusted EBITDA by approximately $11.8 million for the fourth quarter of 2021.

 

Depreciation and amortization expense was $7.9 million for the fourth quarter of 2021 compared to $7.7 million for the fourth quarter of 2020.

 

Investment and other income was $1.8 million for the fourth quarter of 2021 compared to $4.8 million for the fourth quarter of 2020. This decrease primarily reflects the reduced reimbursement received related to the transition services being provided to the buyer of the Company’s former anesthesiology medical group.

 

 

 

Interest expense was $16.6 million for the fourth quarter of 2021 compared to $27.3 million for the fourth quarter of 2020. This decrease primarily reflects the Company’s January 2021 redemption of its $750 million in outstanding principle amount of 5.25% senior notes due 2023 (the “2023 Notes”).

 

Mednax generated income from continuing operations of $40.3 million, or $0.47 per diluted share, for the 2021 fourth quarter, based on a weighted average 86.2 million shares outstanding. This compares with income from continuing operations of $4.5 million, or $0.05 per diluted share, for the 2020 fourth quarter, based on a weighted average 85.1 million shares outstanding.

 

For the fourth quarter of 2021, Mednax reported Adjusted EPS from continuing operations of $0.52, compared to $0.25 for the fourth quarter of 2020. For these periods, Adjusted EPS from continuing operations is defined as diluted income from continuing operations per common and common equivalent share excluding non-cash amortization expense, stock-based compensation expense, and transformational and restructuring related expenses. Funds received from the provider relief fund established by the CARES Act favorably impacted Adjusted EPS by $0.10 for the 2021 fourth quarter.

 

Operating Results from Continuing Operations – Year Ended December 31, 2021

 

For the year ended December 31, 2021, Mednax generated revenue from continuing operations of $1.91 billion, compared to $1.73 billion in the prior-year period. For 2021, the Company recorded $26 million of miscellaneous revenue from the provider relief fund established by the CARES Act compared to $22 million for the prior year. Adjusted EBITDA from continuing operations for the year ended December 31, 2021 was $265.5 million, compared to $219.9 million for the prior year. Funds received from the provider relief fund established by the CARES Act favorably impacted Adjusted EBITDA by approximately $16.5 million for the year ended December 31, 2021, compared to $14.3 million for the prior year. Mednax generated income from continuing operations of $108.0 million, or $1.26 per share, for the year ended December 31, 2021, based on a weighted average 85.8 million shares outstanding, which compares to loss from continuing operations of $9.6 million, or $0.11 per share, based on a weighted average 83.4 million shares outstanding for the prior year. For the year ended December 31, 2021, Mednax reported Adjusted EPS from continuing operations of $1.63, compared to $0.95 in the same period of 2020. For the year ended December 31, 2021 Adjusted EPS also excludes the loss on early extinguishment of debt and gain on sale of building.

 

Financial Position and Cash Flow – Continuing Operations

 

Mednax had cash and cash equivalents of $387 million at December 31, 2021, compared to $1.12 billion on December 31, 2020, and net accounts receivable were $302 million. As previously disclosed, Mednax used $764 million in cash in January 2021 to redeem its $750 million 2023 Notes, including cash premiums and accrued interest.

 

For the fourth quarter of 2021, Mednax generated cash from continuing operations of $75.0 million, compared to $82.2 million fourth the fourth quarter of 2020, primarily reflecting decreases in cash flow from changes in accounts payable and accrued expenses and accounts

 

 

receivable, partially offset by improved results. During the fourth quarter of 2021, the Company used $10.4 million to fund practice acquisitions and $3.2 million in capital expenditures.

 

At December 31, 2021, Mednax had no outstanding borrowings under its $600 million revolving credit facility and had total debt outstanding of $1.0 billion, consisting solely of its 6.25% senior notes due 2027 (the “2027 Notes”), and net debt of $613 million.

 

Subsequent Event – Refinancing Transactions

 

Subsequent to the fourth quarter of 2021, Mednax issued $400 million in 5.375% senior notes due 2030, the proceeds of which were used, together with a new $450 million revolving credit facility, a new $250 million term A loan and cash on hand, to redeem its $1.0 billion in outstanding principle amount of the 2027 Senior Notes and pay related fees and expenses. After reflecting these transactions, the Company’s total debt outstanding was $750 million.

 

Discontinued Operations

 

Discontinued operations for the three and 12 months ended December 31, 2021 and 2020 include the operating results of the Company’s former anesthesiology and radiology medical groups as well as adjustments to the losses on sale for relevant periods.

 

Non-GAAP Measures

 

A reconciliation of Adjusted EBITDA from continuing operations and Adjusted EPS from continuing operations to the most directly comparable GAAP measures for the three and 12 months ended December 31, 2021 and 2020 is provided in the financial tables of this press release.

 

Preliminary 2022 Outlook

 

On a preliminary basis, Mednax anticipates that its 2022 Adjusted EBITDA, as defined above, will be at least $270 million. This outlook does not reflect any additional funds from the provider relief fund established by the CARES Act, which favorably impacted Adjusted EBITDA by approximately $16.5 million for the year ended December 31, 2021.

 

Earnings Conference Call

 

Mednax, Inc. will host an investor conference call to discuss the quarterly results at 9 a.m., ET today. The conference call Webcast may be accessed from the Company’s Website, www.mednax.com. A telephone replay of the conference call will be available from 12:45 p.m. ET today through midnight ET March 3, 2022 by dialing 866.207.1041, access Code 1588129. The replay will also be available at www.mednax.com.

 

ABOUT MEDNAX

 

Mednax, Inc. is a national medical group comprised of the nation’s leading providers of physician services practicing under the Pediatrix® brand. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women,

 

 

babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by 18 pediatric subspecialties, as well as a newly expanded area of primary and urgent care clinics. The group’s high-quality, evidence-based care is bolstered by investments in research, education, quality-improvement and safety initiatives. The company was founded in 1979 as a single affiliated neonatology practice and today provides its highly focused and often critical care services through more than 4,700 affiliated physicians and other clinicians in 38 states and Puerto Rico. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn, Twitter and the Pediatrix blog. Mednax investment information can be found at www.mednax.com/investors.

 

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the COVID-19 pandemic on the Company and its financial condition and results of operations; the effects of economic conditions on the Company’s business; the effects of the Affordable Care Act and potential changes thereto or a repeal thereof; the Company’s relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the impact of surprise billing legislation; the Company’s ability to comply with the terms of its debt financing arrangements; the Company’s transition to a third-party revenue cycle management provider; the impact of the divestiture of the Company’s anesthesiology and radiology medical groups; the impact of management transitions; the timing and contribution of future acquisitions; the effects of share repurchases; and the effects of the Company’s transformation initiatives, including its reorientation on, and growth strategy for, its pediatrics and obstetrics business.

 

###

 

 

 

 

 

 

 

Mednax, Inc.

Consolidated Statements of Income

(in thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended
December 31,

 

 

Twelve Months Ended
December 31,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net revenue

 

$

498,530

 

 

$

416,630

 

 

$

1,911,191

 

 

$

1,733,951

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Practice salaries and benefits

 

 

332,671

 

 

 

284,772

 

 

 

1,297,477

 

 

 

1,193,940

 

Practice supplies and other operating expenses

 

 

27,956

 

 

 

24,235

 

 

 

100,472

 

 

 

90,690

 

General and administrative expenses

 

 

58,981

 

 

 

54,671

 

 

 

263,357

 

 

 

248,947

 

Gain on sale of building

 

 

—

 

 

 

—

 

 

 

(7,280

)

 

 

—

 

Depreciation and amortization

 

 

7,859

 

 

 

7,692

 

 

 

32,147

 

 

 

28,441

 

Transformational and restructuring related expenses

 

 

3,058

 

 

 

12,955

 

 

 

22,100

 

 

 

73,801

 

Total operating expenses

 

 

430,525

 

 

 

384,325

 

 

 

1,708,273

 

 

 

1,635,819

 

Income from operations

 

 

68,005

 

 

 

32,305

 

 

 

202,918

 

 

 

98,132

 

Investment and other income

 

 

1,823

 

 

 

4,849

 

 

 

13,652

 

 

 

17,913

 

Interest expense

 

 

(16,603

)

 

 

(27,302

)

 

 

(68,722

)

 

 

(110,482

)

Loss on early extinguishment of debt

 

 

—

 

 

 

—

 

 

 

(14,532

)

 

 

—

 

Equity in earnings of unconsolidated affiliate

 

 

290

 

 

 

504

 

 

 

1,912

 

 

 

1,585

 

Total non-operating expenses

 

 

(14,490

)

 

 

(21,949

)

 

 

(67,690

)

 

 

(90,984

)

Income (loss) from continuing operations before income taxes

 

 

53,515

 

 

 

10,356

 

 

 

135,228

 

 

 

7,148

 

Income tax provision

 

 

(13,239

)

 

 

(5,869

)

 

 

(27,241

)

 

 

(16,728

)

Income (loss) from continuing operations

 

 

40,276

 

 

 

4,487

 

 

 

107,987

 

 

 

(9,580

)

Income (loss) from discontinued operations, net of tax

 

 

7,234

 

 

 

(68,783

)

 

 

22,950

 

 

 

(786,908

)

Net income (loss)

 

 

47,510

 

 

 

(64,296

)

 

 

130,937

 

 

 

(796,488

)

Net loss attributable to noncontrolling interest

 

 

6

 

 

 

—

 

 

 

27

 

 

 

—

 

Net income (loss) attributable to Mednax, Inc.

 

$

47,516

 

 

$

(64,296

)

 

$

130,964

 

 

$

(796,488

)

Per common and common equivalent share data (diluted):

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations

 

$

0.47

 

 

$

0.05

 

 

$

1.26

 

 

$

(0.11

)

Income (loss) from discontinued operations

 

$

0.08

 

 

$

(0.81

)

 

$

0.27

 

 

$

(9.44

)

Net income (loss) attributable to Mednax, Inc.

 

$

0.55

 

 

$

(0.76

)

 

$

1.53

 

 

$

(9.55

)

Weighted average common shares

 

 

86,245

 

 

 

85,082

 

 

 

85,828

 

 

 

83,395

 

 

 

 

 

 

 

 

 

 

 

Mednax, Inc.

Reconciliation of Income (Loss) from Continuing Operations

to Adjusted EBITDA from Continuing Operations Attributable to Mednax, Inc.

(in thousands)

(Unaudited)

 

 

 

Three Months Ended
December 31,

 

 

Twelve Months Ended
December 31,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Income (loss) from continuing operations attributable to Mednax, Inc.

 

$

40,282

 

 

$

4,487

 

 

$

108,014

 

 

$

(9,580

)

Interest expense

 

 

16,603

 

 

 

27,302

 

 

 

68,722

 

 

 

110,482

 

Gain on sale of building

 

 

—

 

 

 

—

 

 

 

(7,280

)

 

 

—

 

Loss on early extinguishment of debt

 

 

—

 

 

 

—

 

 

 

14,532

 

 

 

—

 

Income tax provision

 

 

13,239

 

 

 

5,869

 

 

 

27,241

 

 

 

16,728

 

Depreciation and amortization expense

 

 

7,859

 

 

 

7,692

 

 

 

32,147

 

 

 

28,441

 

Transformational and restructuring related expenses

 

 

3,058

 

 

 

12,955

 

 

 

22,100

 

 

 

73,801

 

Adjusted EBITDA from continuing operations attributable to Mednax, Inc.

 

$

81,041

 

 

$

58,305

 

 

$

265,476

 

 

$

219,872

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Mednax, Inc.

Reconciliation of Diluted Income (Loss) from Continuing Operations per Share

to Adjusted Income from Continuing Operations per Diluted Share (“Adjusted EPS”)

(in thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended
December 31,

 

 

 

2021

 

 

2020

 

Weighted average diluted shares outstanding

 

 

86,245

 

 

 

 

 

 

85,082

 

 

 

 

Income (loss) from continuing operations and diluted income from continuing operations per share attributable to Mednax, Inc.

 

$

40,282

 

 

$

0.47

 

 

$

4,487

 

 

$

0.05

 

Adjustments (1):

 

 

 

 

 

 

 

 

 

 

 

 

Amortization (net of tax of $593 and $662)

 

 

1,780

 

 

 

0.02

 

 

 

1,986

 

 

 

0.02

 

Stock-based compensation (net of tax of $1,005 and $731)

 

 

3,015

 

 

 

0.03

 

 

 

2,191

 

 

 

0.03

 

Transformational and restructuring expenses (net of tax of $764 and $3,239)

 

 

2,294

 

 

 

0.03

 

 

 

9,716

 

 

 

0.12

 

Net impact from discrete tax events

 

 

(2,672

)

 

 

(0.03

)

 

 

2,661

 

 

 

0.03

 

Adjusted income and diluted EPS from continuing operations attributable to Mednax, Inc.

 

$

44,699

 

 

$

0.52

 

 

$

21,041

 

 

$

0.25

 

 

(1)
A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended December 31, 2021 and 2020.

 

 

 

 

Twelve Months Ended
December 31,

 

 

 

2021

 

 

2020

 

Weighted average diluted shares outstanding

 

 

85,828

 

 

 

 

 

 

83,395

 

 

 

 

Income (loss) from continuing operations and diluted income from continuing operations per share attributable to Mednax, Inc.

 

$

108,014

 

 

$

1.26

 

 

$

(9,580

)

 

$

(0.11

)

Adjustments (1):

 

 

 

 

 

 

 

 

 

 

 

 

Amortization (net of tax of $2,643 and $2,294)

 

 

7,928

 

 

 

0.09

 

 

 

6,882

 

 

 

0.08

 

Stock-based compensation (net of tax of $4,742 and $5,281)

 

 

14,226

 

 

 

0.16

 

 

 

15,843

 

 

 

0.19

 

Transformational and restructuring related expenses (net of tax of $5,525 and $18,450)

 

 

16,575

 

 

 

0.19

 

 

 

55,351

 

 

 

0.66

 

Gain on sale of building (net of tax of $1,820)

 

 

(5,460

)

 

 

(0.06

)

 

 

—

 

 

 

—

 

Loss on early extinguishment of debt (net of tax of $3,633)

 

 

10,899

 

 

 

0.13

 

 

 

—

 

 

 

—

 

Net impact from discrete tax events

 

 

(12,156

)

 

 

(0.14

)

 

 

10,541

 

 

 

0.13

 

Adjusted income and diluted EPS from continuing operations attributable to Mednax, Inc.

 

$

140,026

 

 

$

1.63

 

 

$

79,037

 

 

$

0.95

 

 

(1)
A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the twelve months ended December 31, 2021 and 2020.

 

 

 

 

 

 

 

 

 

 

 

 

 

Mednax, Inc.

Balance Sheet Highlights

(in thousands)

(Unaudited)

 



 

As of
December 31, 2021

 

 

As of
December 31, 2020

 

Assets:

 



 

 



 

Cash and cash equivalents

 

$

387,391

 

 

$

1,123,843

 

Investments

 

 

99,715

 

 

 

104,870

 

Accounts receivable, net

 

 

301,775

 

 

 

241,931

 

Other current assets

 

 

51,683

 

 

 

78,704

 

Intangible assets, net

 

 

21,565

 

 

 

26,642

 

Operating and finance lease right-of-use assets

 

 

65,461

 

 

 

55,972

 

Goodwill, other assets, property and equipment

 

 

1,794,956

 

 

 

1,715,986

 

Total assets

 

$

2,722,546

 

 

$

3,347,948

 

Liabilites and equity:

 



 

 



 

Accounts payable and accrued expenses

 

$

394,118

 

 

$

423,183

 

Total debt, net

 

 

1,004,748

 

 

 

1,744,805

 

Operating lease liabilities

 

 

61,080

 

 

 

59,903

 

Other liabilities

 

 

365,908

 

 

 

372,340

 

Total liabilities

 

 

1,825,854

 

 

 

2,600,231

 

Total equity

 

 

896,692

 

 

 

747,717

 

Total liabilities and equity

 

$

2,722,546

 

 

$

3,347,948

 

 

 

 

 

 

 

 

 

 

 

Mednax, Inc.

Reconciliation of Income from Continuing Operations

to Forward-Looking Adjusted EBITDA from Continuing Operations Attributable to Mednax, Inc.

(in thousands)

(Unaudited)

 

 

 

Year Ended
December 31, 2022

 

 

 

 

 

Income from continuing operations attributable to Mednax, Inc.

 

$

100,000

 

Interest expense

 

 

36,000

 

Loss on early extinguishment of debt

 

 

57,000

 

Income tax provision

 

 

43,000

 

Depreciation and amortization expense

 

 

34,000

 

Adjusted EBITDA from continuing operations attributable to Mednax, Inc.

 

$

270,000

 

 

 

 

 

 GRAPHIC 3 img163251054_0.jpg GRAPHIC begin 644 img163251054_0.jpg M_]C_X 02D9)1@ ! 0$!+ $L #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" "8 R\# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "ORK_;I_:Z^+/PJ_:8\1>&O"WB^?2M$MK:T>*U2)&"L\09CDCN:_52OQ+_ M ."E7_)X7BS_ *\['_T2*143#_X;\^/?_0_W7_?B/_"OIG]@W]OCQ5XF^*Q\ M&?$_7?[4M]< CTN_F14,%T.D1(_A<=/<5^<=26]Q-9W$-Q;RM!<0NLD4L9PR M.IR&!]00*$59'])]%?.W[#W[2T/[1_P=M;J]F7_A+-'"V6L0YY:0#Y)@/1P, M_4-7T33,PK'\7^+-+\"^%]4\0ZW=+9:3IMN]U_M/4(?@_X>N\VUJR76ORQ-]^3K%;'V7AV'J5]*!K4\-^(?_!1KXR>) MO'&LZGX?\3S:!H<]PQL=-BB1A#"#A 21RV,$GU)KG?\ AOSX]_\ 0_W7_?B/ M_"OGRBI-+(_7[_@F;\=/''QO\+^-[KQMKLFN3V%_#%;/(BKY:M%DC@>M?:M? MG;_P1U_Y$WXC_P#82M__ $37Z)51F]S\XO\ @I!^TY\2_@M\7M TCP9XGFT7 M3[C2O/EACC5@TGF$;N1Z5\F?\-^?'O\ Z'^Z_P"_$?\ A7L7_!7+_DO/AC_L M"?\ M4U\-4BTM#Z#_P"&_/CW_P!#_=?]^(_\*/\ AOSX]_\ 0_W7_?B/_"OG MY8W?[L;N/55)I?(E_P">,O\ W[/^%(+(^@/^&_/CW_T/]U_WXC_PH_X;\^/? M_0_W7_?B/_"OG_R9?^>,O_?L_P"%'DR_\\9?^_9_PH"R/H#_ (;\^/?_ $/] MU_WXC_PK],_^">?Q6\4_&+X C7_%^JOK&K?VG3+_S MQE_[]G_"OV(_X)4*R_LO@,K*?[8N^&!!^\*:$]C[(K\C?VN/VROC%\//VCO' M/ASP]XRN-.T;3[Q8[:U6%"(U\M3C)'J37ZY5^$O[=O\ R=O\2?\ K_7_ -%) M0*):_P"&_/CW_P!#_=?]^(_\*/\ AOSX]_\ 0_W7_?B/_"OGRFF15X)YI%V1 M]#+^W]\>U8'_ (3^Y./6"/'\JWM$_P""EGQ\T5P6\2V&HIGE+W38WS[9&"*^ M6_.0=6 I(YHY/N.K_P"Z0: LC](OA;_P5\NTN(;;XA>"XVMR0K:AH4IW+ZLT M3]?HIK[O^#O[07@'X]:.=0\%^(;?5-@S-:$[+F#V>,_,/Y5_/C6UX-\::]\/ M?$=IK_AK5;K1=8M6#17=I(488['LP]CD4[D\I_1S17R/^P_^W)8_M':;_P ( MSXF\C3/B#91;WC3Y8M1C'66(=F'\2=NHXKZXID!7PI_P4T_: \?? ^3P*O@G MQ!+H8U#[1]I\N-6\S;MV]1VR:^ZZ_-'_ (+%?Z[X:_\ ;W_):!H^7?\ AOSX M]_\ 0_W7_?B/_"OIO]A?_@H1X@UKXB?\(9\5M;74+?6G5-,U>=5C^SW'01.1 MQM?L3T./6OSAI59E8,K%64Y#*<$'L0?6E+?%D^KZ+)I=Y.]K M)$B@N@3:<@=LFOSPKZS_ ."7'_)WFE?]@74/_08ZDMK0_:"BBBJ,PHHHH \\ M_:"^+%K\$/@[XH\9W3+NTVT8VT;=)+AOEB3\7*Y]LU^*4G[97QTDD=_^%J^) M4W,6VK=+A0>A'I7[9_ WX MH6/QF^$_AGQC8,#'JEFDLB9R8Y<8D0^X8$5_/-7Z5?\ !(_XV?+XD^%NH3\J M3J^E*S?PD@3HH]CM?_@1H0-'Z4T444R HHHH ^%/^"BGBKXU?!=K#QUX#\77 MEKX/GVVFH6*1(XLI^B29(SL?I[,!_>KX:_X;]^/?_0_W7_?B/_"OVV\9^#]) M^('A75?#FNVB7VD:G;O;7-O(.&1AC\".H/8@&OP;_:8^ 6K?LW_%C4_">H!Y MK'/VC3+YEP+JU8G8W^\/NL.Q!I%H]Q^ 7_!1_P")/AKXIZ-YCZC_9/^S0#1^A= M(S!5+,0 !DD]J6OC7_@I#^U/_P *8^'/_"&^'[OR_&/B6%H]\;?/9V9RLDOL MS(CI'AK1=UF]U!&K_;IP?WCY(^Z"-H MQUP37A__ W[\>_^A_NO^_$?^%?/:C;QS^=>B? 'X)ZU^T%\4=(\&Z*K(;I] M]Y>;^,/&?C"]G\"Z;NMX;9 MH40:A&O#7C M"?3-%L9(!;VJ1(P0-;QL>2/5B?QKQ+_AOSX]_P#0_P!U_P!^(_\ "K/_ 4, M_P"3P/B!_P!=;;_TEBKYSJ32Q^Z7["/Q&\1?%;]FGP[XD\5:DVK:U!Z 5] U\L_\$S?^3/\ PG_U\7O_ *4/7U-5$'QM_P %+OC=XU^" M/@'PA?\ @K6Y-#N[W49(9Y(T5MZ! 0.1ZU^?'_#?GQ[_ .A_NO\ OQ'_ (5] MG?\ !8/_ ))AX#_["TW_ *+%?E=292V/OO\ 8[_X*,^++;XH0:%\5]>_M7P[ MK++;Q:C/&J&PG)PK,0/N-G!].#7ZK(ZR(KHP96&0RG((]:_FM(# @]*_5G_@ MFG^V$?'FBP_"OQ??;O$>FP_\2B\G;YKVV4?ZHD]9$'YK]*!-'WW1113)/#?V MV/'VO?#']FCQAXE\,W[:7K=DMN;>Z10Q3=<1JW!]58C\:_*'_AOWX]_]#_=? M]^(_\*_3[_@HM_R9[X]_W+7_ -*HJ_#ZDRXGW=^Q?^V%\7OB9^TQX*\->)/& M-QJ>B7TEPMQ:O$BAPMO*Z\@9^\H/X5^LM?AK_P $]?\ D\3X=_\ 7:Z_]))J M_XN&_NQQCEC^GO7YR?&3_@K1XP\07,]G\.- M#M?#6G9VIJ&IJ+BZ<=,[/NKGJ.I%?&OQ4^*_BCXT>,KOQ/XNU275-4N"=NXD M1P)VCB7HJCT'XUR-*Y:1ZUXA_:T^,WBJ9WU#XDZ^ZL2?*AN?*C7V 4# KGD^ M.WQ(CDWKX]\0JVD4*%W_ " S6A)X6UV&/?)H M.K1Q]=[V$RC\RM!1ZOX6_;2^-_@^XBDLOB/K%Q'&V\0^$M9MM:TJ<<36[Y*-W5QU5AZ&NHK\.OV#==^*=A\ M>-*T_P"&4K-]J=7U>UN"QL3:@C>\X'3 ^ZPYS@"OW#7=M&[&['..F:HAJPZB MBB@04444 %%%% !1110 5^)?_!2K_D\+Q9_UYV/_ *)%?MI7XE_\%*O^3PO% MG_7G8_\ HD4F5'<^8***[/Q?\*-;\&^"?!OBVZB\W0O%%L\UG=(/E61&*O$W MHPQGW%(L[;]D?]H:]_9M^,FF^(@\CZ%=$6>L6JGB2V8C+ ?WD/S#Z5^[VCZO M9Z_I-GJ>G7"7=A>0I<6]Q&XN;B4Y:21R6 M9B??ED4'YY\>KDE M T@HKO/'WP=UKX;^#O!>NZVAM6\56TE]:6CKATMU;:CM_O\ W@/0CUK@Z0S] M0?\ @CK_ ,B;\1_^PE;_ /HFOT2K\[?^".O_ ")OQ'_["5O_ .B:_1*J,WN? MDC_P5R_Y+SX8_P"P)_[5-?#5?D?^ $7 M_P 37P3_ ,$K/B3X3\%_!WQ/:Z_XDTO1KF763(D-]=I"S+Y8Y 8C(K[8_P"% M^?#;_H?/#O\ X,H?_BJHA[F]_P *_P#"_P#T+6D?^ $7_P 31_PK_P +_P#0 MM:1_X 1?_$U@_P#"^_AM_P!#YX=_\&4/_P 51_POOX;?]#YX=_\ !E#_ /%4 M"-[_ (5_X7_Z%K2/_ "+_P")K4TW2;'1K?[/I]G;V,&2WE6T2QKD]3A0!FN= MT/XN>"/$^IQ:=I'BW1M3OY<^7;6E]')(V!DX4')XKK: "OPE_;M_Y.W^)/\ MU_K_ .BDK]VJ_"7]NW_D[?XD_P#7^O\ Z*2DRH[G@U?M+^P#X \+ZU^R3X!O M-0\-:/?7_]>\W_H^2DAR/ M9F^%/@EA@^#M (]]+@_^)KBO'G[(_P '_B19O;ZSX!T;+#"S6=LMM(A]08\< M_6O7Z*H@_(_]KK_@FOJ?P?TF]\7_ \N+KQ%X7MP9;O3;@;[RRC'5U(_UJ = M> 1Z8%?#8.X9K^E*2-9HV1U5T8%65AD$'J"*_$']O[X 6_P%^/E[#I%N+?PW MK\?]J:?&H^6'OT>_X) ?$F:/4O''@.XES;LD6KVBL>C9\N0+Z"=>\5V%F MUUH^A3P0ZA)'R8/.W;'(_NY7&>Q(I&A#X$\<:U\-?&&E>)_#UXUAK.F3K/;S M+ZCJK#NI&01W!-?NS^S#^T1HO[2GPNL?$VFE+?48\6^J:=NRUI<@?,O^Z?O* M>X/UK\"*]H_9/_:3U;]F7XHVNO6QDN=!NRMOK&G*>+B#/W@/[Z?>4_4=Z!-7 M/WKKX_\ ^"J7_)J-U_V&;/\ ]GKZH\'^+M)\>>&-,\0Z%>QZAI&HP+<6US$< MAT89'T/8CL17RO\ \%4O^34;K_L,V?\ [/39"W/QLKZS_P""7'_)WFE?]@74 M/_08Z^3*^L_^"7'_ "=YI7_8%U#_ -!CI%O8_:"BBBJ,PK,\3>(K'PCX=U/7 M-3F6VT[3K:2[N)FZ)&BEF/Y"M.OB'_@JG\;/^$'^#=EX'L+CR]5\5S;9PAPR MV<1#2?\ ?3;%]QNH _+OXQ?$J^^,7Q2\2^,M1+?:-7O'G5&.?*BSB./Z*@5? MPK'\&^$=3\?>+-(\-Z+;_:M5U2Y2TMHN@+L<#)[ =2>P!K&K[M_X)0?!?_A+ M/BIJ_P 0+Z#=I_AN'[/9LR\&[E!!(/JL>?\ OX*1KL?#NK:7=:%JU[IM]"UO M>V<[V\\+C!1U8A@?Q%=A\"_BE=_!7XN>&/&=HS#^R[Q7N$&?WENWRRJ?7*$\ M>H%?07_!3GX+_P#"L_V@I/$=E!Y>C^+HOMRE1A5NEXF7ZDX?_@5?(5(.A_2+ MH>M6GB/1;#5;"59[*]@2XAD4Y#(RA@?R-7J^+O\ @EO\;/\ A87P-?PA?W'F M:OX2E^S(&/S/:-S$?4A>5S[5]HU1D%%%% !7SM^V[^S#;_M*?">>WLHHT\7Z M.&N]'N#@%GQ\T#'^ZX&/9@I]:^B:* /YLKZQN-,O;BSO()+6\MY&BF@E7:T; MJ<,I'8@BM+P=XNU7P#XJTKQ'H=TUEJ^EW"75M.O\+J>A]01D$=P2*^^O^"HG M[*7]BZDWQA\,6>+&\=8_$%O"O$)OV97^+M[<1V=M8VK#4;'=^\BO%&# !W+-C;ZA@:_%_P",?Q7UKXW?$C6_ M&6O2%KW4IBR0YRMO".(XE] JX'YUSL/B+5+?P_=:%%J%PFC74Z74]@LA$,DJ M#"N5Z%@#@&LZ@25A\,,MS-'#!$\T\K"..*,99V)P% [DDU^V'[!/[*\?[.GP MM2]U>!?^$VUY%N-2D(YMTQE+<'T4=?5OI7R+_P $P_V4?^$V\1CXK^)K/=H> MDRE-&MYE^6YN1]Z;'=4Z#U;Z5^K5!,F%%%%,D**** "BBB@ HHHH **** /P MX_X*&?\ )X'Q _ZZVW_I+%7SG7T9_P %#/\ D\#X@?\ 76V_])8J^_^E#U]35\L_\ !,W_ ),_\)_]?%[_ .E#U]351FS\ M_?\ @L)_R3#P'_V%IO\ T6*_*ZOU1_X+"?\ ),/ ?_86F_\ 18K\KJ3+CL%7 M_#_B#4?"FNV&LZ1>26&JV$RW%M=0G#1R*<@BM7PO\/=<\9:%XGU;1[-KVV\. M6L=[J"Q\O' [[/, [@'KZ"N;Z\BD,_=?]CC]J+3OVG/AC#J+-';>*M-"V^L: M>IY27'$JC^X^,CTY':O?*_GX_9W^/&N_LZ?$[3O%VBLTL<9$-_8EB$O+8D;X MV]^X/8@5^[WPQ^).A?%SP+I/BSPW=K>:3J4(EC8$;D/\2,.S*<@CU%40T>+? M\%%O^3/?'O\ N6O_ *515^'U?N#_ ,%%O^3/?'O^Y:_^E45?A]4L<=CZ)_X) MZ_\ )XGP[_Z[77_I)-7[E5^&O_!/7_D\3X=_]=KK_P!))J_KGYB>^17ZK_\ !17XD3?#?]ECQ,]I*T%[K#QZ1#(APR^:3N(_X"K# M\:_$15"J !@#@4#B+7U+^Q?^P]J_[3FH/KFKSS:'X!LY?+FO8U_?7L@ZQ0Y] M.[]L]S7S_P##3P)>_%#XA>'/".GY%YK-]'9HP_A#'YF_!EVR6T**,9P.6/NQR3[F@&SF_A;^SM\.O@WI4%CX4\*:=I_ ME@9NFA62X#?&[]B;X4? M'+3YAJ?ARWT?5RI$6L:/&MO/&WJ0HVN,]0PYQU%?EY\:/V ?B=\*_B1I7AK3 MM.D\5:?K=T+;2]6LHR(W8\[9A_RR8 $G/&%)!K]O**!W/#OV2_V7=$_9@^'< M>E6HCO?$5Z%FU?5=OS3RX^XO<1KT _'J:]QHHH$%%%% !1110 4444 %%%% M!7XE_P#!2K_D\+Q9_P!>=C_Z)%?MI7XE_P#!2K_D\+Q9_P!>=C_Z)%)E1W/F M"OUN_9_^ ^D_M%?\$Z_#7A'4PL=Q);RS6%YMRUKV>".X)K\D:_<#_ M ()U_P#)H?@3_KE+_P"C6I(H]01@@]P169:WEQ8S>;;3R6\N"OF0N5;!&",CL1Q7ZE?\%0_P!E?_A*_#P^ M+/AJSW:OI,0BUJ"%>;BU'2;'=H^_^R3Z5^5_6AE+4*^E?V$OV8)?VCOBS%)J M=NQ\&:"R76J2$86=LYCMP?5R.?\ 9!]J\#\&^$-6\?\ BK2O#FA6CWVKZI<) M;6T"#EG8XR?0#J3V K]Y_P!FKX#Z3^SI\)M)\(Z:$EN8U\_4+U5P;JZ8#>Y] MNP] HH0FSX#_ ."OUO%:>./AQ!#&L4,>ES(D:#"JHDP !V %?GW7Z$?\%AO^ M2@?#W_L&S_\ HTU^>]#!;'Z@_P#!'7_D3?B/_P!A*W_]$U^B5?G;_P $=?\ MD3?B/_V$K?\ ]$U^B540]S\D?^"N7_)>?#'_ &!/_:IKX:K[E_X*Y?\ )>?# M'_8$_P#:IKX:J66MA-H/:C:/2O9O@I^R/\2?V@O#]YK/@O2K:^L+2X^RRO-= MQPD28SC#$9X->A_\.R_CW_T+MA_X,X?_ (J@=SY6VCTHVCTKZI_X=E_'O_H7 M;#_P9P__ !5'_#LOX]_]"[8?^#.'_P"*H"Z,W_@G(H'[77@WC^"Z_P#1#5^W MM?F#^QK^PS\7/@[^T-X;\5^)]&M+31;)9Q-+%?12,-T3*/E!R>2*_3ZJ,WN% M?A+^W;_R=O\ $G_K_7_T4E?NU7X2_MV_\G;_ !)_Z_U_]%)28X[G@U?N'_P3 MM_Y,]^'O_7O-_P"CY*_#ROW#_P""=O\ R9[\/?\ KWF_]'R4D.1](44451 5 M^=O_ 6(T6&7P?\ #G5MH%Q!?W5ON[LK(AQ^!4_G7Z)5^:?_ 6'\:0._P . MO"<4@-TGVG4YX\\B-ML<9_-7H&MS\V*^NO\ @EG?26W[6=E K$1W&BWRNH[X M",/Y?K7R+7V=_P $H?#LNI_M-7>JHI,.EZ)<>8<< RLBK_Z":DM['["U^:/_ M 6*_P!=\-?^WO\ DM?I=7YH_P#!8K_7?#7_ +>_Y+39"W/S:K]%_P#@DAH. MG^*M%^,.CZM:1WVF7T=G;W-M,NY)(V68%2/H:_.BOTF_X(X?>^*7^]8?REI( MM['RM^V1^R[J'[,?Q.EL8UDN?"6ILT^C7S#.4SS"Y_OID#W&#WKP.OZ!_P!H M7X$Z#^T1\,=2\(ZXBH91YME>A^#_CS5_"/ MB2U-KJNFS&-_[LB]5D0]U88(/O3!,^M?^":5_V!=0_]!CI ]C]H****HS&LPC4LQ"J MHR2>U?A-^VY\:C\K6\WFZ-IS_ -E:;@_+Y,1(+C_>?>V?0BOU5_;N M^-G_ I#]G?7[ZUN/(US5E_LK3=IPPEE!#./=$W-^ K\,AT%)EQ#EL #<3P! M7[P?L6?!&M;\4V5QJ6@Z;>I=W-G:A3)-L.Y4^8@8+!<^V:_2T?\%?OAXH '@OQ&!V MYA_^*H0,]5_X*+_!4_%[]G'5KFRM_.USPVW]K69498H@_?(/8IR?]P5^)JL& M4,.A&:_5BZ_X*[?#>]MI;>X\#^(IH)D,?#>LSRA]8LH_P"S=27/(GB 4M]&&TY[Y- 2/>****9 4444 9OB3P[IWB[0 M-0T75[2.^TO4('MKFWE&5DC88(/Y_A7X&?M+?".W^!?QN\3^#++4HM5L=/G# M6\\;AF6-QN6-\='4':1ZBOV+_;*_:8LOV9_A+=:I&\OPQU;5KW7M5O-3U&YDO-0O)FN+BXF8L\DC'+,2>Y)I,N)4KNO M@9\.;7XN?%WPMX/O=4AT:SU:]6":\F;&U.I5?]I@,#W-<+3X+B6UN(IX)7@G MB=9(Y8SAD8'(8'L00#2*/Z-_!OA'2O /A72_#NAVB6.D:;;K;6UO&,!448_, M]3[DULU\Q_L&_M31?M&_"Q+;59T_X370E6WU2,GYIUQA+@#T8#GT;/K7TY5& M04444 %%%% !1110 4444 %%%% 'XOJ:OEG_@F; M_P F?^$_^OB]_P#2AZ^IJHS9^?O_ 6$_P"28> _^PM-_P"BQ7Y75^J/_!83 M_DF'@/\ ["TW_HL5^5U)EQV/O3_@D/90:E\4/B3:74*7%K/X?ABEAD7*NK3D M%2.X()KRK]NW]DNX_9N^(9U'1X'?P)KDK2:?+CBTD/+6S'VZKZCZ5ZW_ ,$> MO^2N?$+_ + =O_Z4&OTE^,/PFT'XW?#W5O!_B.W$^G7\>T. -\$@^Y*A[,IY M%!-[,_G@KZU_X)^_M=2?L^^.AX;\0W3?\(%KLRK.7)(L+@\+.!V4\!L=L'M7 MA'QR^"^O? +XDZKX/\01?Z1:ONM[I5(CNX"3LE3V(ZCL017 D Y!Z4BS]OO^ M"A\T=S^QOXZEAD66*2*T=)$.593=0D$'N*_$&OK3PW^UU)XF_8P\;_"'Q9=M M)JEG!;'0;R4DF>%;F,M;L?[R $K_ +((["ODNAB1]$_\$]?^3Q/AW_UVNO\ MTDFK]RJ_#7_@GK_R>)\._P#KM=?^DDU?N531,CX!_P""P6IR6_PI\#6*L1%= M:Q(SKZ[(@1_.ORJK]9O^"NV@27OP-\,:NH_=Z=K:QO\ ]M4*C_T&OR9I,J.Q M]2_\$S=)@U;]KSPYYZJZVMA>W* ]G6,!2/IFOVNK\,_^"?WC2#P+^UGX)NKI MUCAOVFTLLQPJF9-H)/U K]S*HF6X4444$A1110 4444 %%%% !1110 4444 M%%%% !7XE_\ !2K_ )/"\6?]>=C_ .B17[:5^)?_ 4J_P"3PO%G_7G8_P#H MD4F5'<^8*_<#_@G7_P FA^!/^N4O_HUJ_#^OW _X)U_\FA^!/^N4O_HUJ2'( M^C;RSAU"TGM;F)9[>9&CDB<95U(P01Z$&OP\_;B_9DF_9M^+5Q%8PM_PAVLE M[O2)L96)<_/;D^J$\>JD>]?N37G_ ,:?@;X2^/OA>WT#Q?8&]L;>[BO8C&VR M1)$;/#=0&&5/J":HE,^.O^"7?[*__"*Z ?BUXEL]NKZI$8M$AF7FWM3PTV#T M:3H/]G/]ZOT%J&SLX-.LX+6UA2WMH$6**&-0JHBC 4 = *FH _+3_@L-_R M4#X>_P#8-G_]&FOSWK]"/^"PW_)0/A[_ -@V?_T::_/>I9:V/U!_X(Z_\B;\ M1_\ L)6__HFOT2K\[?\ @CK_ ,B;\1_^PE;_ /HFOT2JB'N?DC_P5R_Y+SX8 M_P"P)_[5-?#5?M7-[>ZB;N-M-M5E0)L P277!R*^F?^ M'MGP:_Z!?BS_ ,%T?_QVF2UJ?;-%?$W_ ]L^#/_ $"_%G_@NC_^.T?\/;/@ MS_T"_%G_ (+H_P#X[3%9GVS17Q-_P]L^#/\ T"_%G_@NC_\ CM?0/[.O[2GA M;]ISPQJ6N^%+?4K>SL+O[%*NIP+$Y?8KY #-D884 >L5^$O[=O\ R=O\2?\ MK_7_ -%)7[M5^$O[=O\ R=O\2?\ K_7_ -%)28X[G@U?N'_P3M_Y,]^'O_7O M-_Z/DK\/*_13]EC_ (*-> /@;\!_"W@G6M%UV[U+2HI$FFM(4:)BTK.-I+ ] M&%)#D?I_17PN?^"NGPLQQX<\3'_MA'_\57%^-_\ @L)ID=I+'X0^']U<71'[ MNXU>["1*?>-!N/X,*HFS/O;XD?$?P_\ "?P;J7BCQ/J$>FZ181EY)7/+''"( M/XG8\ #K7X.?M%?&S4OV@_BYKGC34%:".[?R[*T)R+:V3B-/KCD^I)-6/CI^ MTMX__:*UE+WQCK#3VL+$VNEVP\NTML_W4'4_[1R3CK7EO>D6E8*_6+_@DS\' MY?"OPKUSQY?0&*Y\2W BM"PP3:PY /T9RQ'M7Y__ ++/[-VM?M,?$ZST"QCD M@T.W99M8U, [;:WSR ?[[=%'X]J_=WPOX9T[P;X^*7^]8?REI(M['Z6U\F_M_?LB1?M" M^ SX@\/VRCQ[H<+-:E1@WT R6MV/<]2OH:5_P!@74/_ $&.ODROK/\ X):5_V! M=0_]!CH$]C]H***X/XZ?%*R^"_PE\3^,KYAY>EV;RQ1YP9)2,1H/\D :0^^U=B_7=7Q?5[7-;O?$VM: MAJ^HS&XU#4+B2ZN)3_%([%F/YDUL_"_P#J'Q3^(GAWPCI:DWNL7L=HK8R(PS M#7I?BJ+= M;!CA5O(Q\OXLF5QZBOC+Q)X?O?"?B+5-$U*)H-0TVZDM)XV&"'1BIX]\9_&E M\,^)+[P;XDTK7]+E:'4=,N8[NWD4X(=&!'/OC'XT#/Z0:*X[X/\ Q(L/B]\, M?#?C#3F5K;5K..X*K_ Y&'3\&##\*[&J,@K*\4>)],\%^'-2UW6;N.QTK3H' MN;FXD.%1%&2?_K=S6K7Y9_\ !4#]J[_A)]:;X1^&+S.E:=()-=N(6XGN!RMO MD=53JW^U@?PT#W/EC]JC]H?4_P!I3XLZAXFNC)!I$)-MI%@QXM[8'YM6I?P5X;E2>[WCY+NX^]';^X_B; MV '>I--C2;_@GOXE7]DG_A9NVY'BP-_:7]A[>?[,VCG'7SAQVKY 5MP M!'0U_2A]GB\CR?+7R=NSR]HV[<8QCTQ7XK_\% _V77_9_P#BL^KZ-;%?!?B2 M1[BR*CY;6?K);GTY.Y?8^U,E,\?_ &>_CAK/[//Q3TGQCHY:1;=O+O;/.%NK M9C\\9'KCD'L0*_>KX>^/=&^*'@O2/%/A^Z6\TG5+=;B"13R 1RI]&!R"/45_ M.=7W'_P3._:M_P"%8^,A\-?$MYL\+Z]/G3IIGPEE>-QMR> DG3V.* DC]<** M**9 45^5_P >/^"DGQ;^'/QF\9>&-)313IFDZG-:6_G6FY]BM@9.>37!_P## MUCXU_P!S0/\ P"_^O059G[&45X?^QC\8=>^._P"S[H7C+Q*+8:O>3W4_^E#U]35\L_\ M!,W_ ),_\)_]?%[_ .E#U]351FS\_?\ @L)_R3#P'_V%IO\ T6*_*ZOU1_X+ M"?\ ),/ ?_86F_\ 18K\KJ3+CL??7_!'K_DKOQ"_[ =O_P"E!K]6:_*;_@CU M_P E=^(7_8#M_P#TH-?JS0B'N?./[;7[*=G^TQ\-F%E'%;^--'5I])O&&-YQ MEH'/]Q\?@<&OQ%U72KW0=4N]-U&UDLK^TE:"XMIEVO%(IPRD>H(K^DBOSO\ M^"F/['O_ D%C1 M14EGT3_P3U_Y/$^'?_7:Z_\ 22:OW*K\-?\ @GK_ ,GB?#O_ *[77_I)-7[E M52(D>-_M??"AOC/^SOXQ\-P('U!K0W5EQDB>+YUP/4X(_&OP197C9DD0QR*2 MKHW56!P0?<&OZ4J_&S_@HW^RW(XZ!C MEE_$4!$^1;&^N-+OK:]LY6@N[:59X95ZHZD,I_,"OW;_ &0?VE-*_:4^$]AJ MT<\:>)+&-;;6;#<-\4X&-^/[K_>!]R.U?@]79?";XO\ BSX(>,+?Q+X.U632 M]2C&UP/FBG3/*2(>&4^]!35S^B&BOS^^$_\ P5Q\(:KI\-O\0O#E_H.I@!7N M])47-M(W=MI(9![9:O5;K_@IM\!K>U,J^(;ZX;&?)AL'+_3G _6F19GU97FG MQ@_:-^'_ ,"9='A\9>((=+N-5G6"W@^_)@G'F,HY6,'JQXKXA^-7_!7*&;3Y M[#X7>&IX[J0%4UC754"+W6 $Y/IN)'M7YX>-/&VO?$;Q)>:_XFU6YUK5[MMT MMU=N68^P]%'8#@4A\I_1E:7<%_:PW-M,EQ;S()(Y8V#*ZD9!!'4$5-7Y)_L$ M_MZ3?">ZLOA]\0+UY_!LSB+3]4F8LVEL3PCGO"3_ -\_2OUIAF2XA26)UDBD M4,KJ\MH+;[##Y8VO&S-NYYY KZZH$%%%% !1110 5^)?_!2K_D\+Q9_UYV/ M_HD5^VE?'7[0_P#P3=T']H3XL:IXYOO&VJZ-0I&8RJ;<#;U_&O?*9+/R1_X*Y?\ )>?# M'_8$_P#:IKX:K]K?VI_V#-&_:D\;:;XDU'Q;J6@S65G]C6WL[>*16&[=N);G M->,?\.=/"W_12=<_\ 8*129^7-%?J-_PYT\+?]%)US_P!@H_X%O\ HI.N M?^ ,%*P^9'Y%O^BDZY_X P5]/_LI_LOZ?^ROX.U;P M_IVO7FOQ:A??;FGO(4C9#L5-H"\8^7/XTQ-Z'MU?A+^W;_R=O\2?^O\ 7_T4 ME?NU7Q1\:_\ @F+X?^-/Q3\0^-KOQUJVF7&L3B=[2WM(72,A0N 3R>G>F2C\ M@Z*_4;_ASIX6_P"BDZY_X P4?\.=/"W_ $4G7/\ P!@J;%\R/RYHK]1O^'.G MA;O\2=,%;6A?\ !(/X=6,X?4_&'B/5X\\Q_N8 ?Q5 MYP/>OIK]FS]@7XB?'Z^MKZ]LYO"'A L#+JNHPE)95[B"(\L3_>.%Y'6OU&^% M?[$_P<^#]Q%=Z'X.M;C48N4U#5";N=?HSYQ^ KW)5"*%4!548 P!3%S'!?! M7X(^$_@'X)MO#'A+3UL[./YYIW^::ZDQS)(W5F/Z=!7?444R K\T?^"Q7^N^ M&O\ V]_R6OTNKYV_:R_8WTK]JYO#S:EXEOO#_P#8_F[/L4$%O^BDZY_X P5]"_LE_L;Z5^R>?$ITW MQ+?>(?[;,!?[;!''Y7EAL8V]<[N_I2*;T/HBBBBF05=4TRTUK3;K3[^WCN[* MZB:&>WF4,DB,,,I'<$$U^(_[;W[*-W^S/\2&DTZ&2;P/K,C2Z5=')$!ZM;.? M[RYXSU&*_<*N$^-GP:\/?'KX=ZIX/\2P%[*\7,<\8'FVTH^Y+&3T93^8R.] MT['\\]?6?_!+C_D[S2O^P+J'_H,=?20_X(Y^%P!_QOT"_X))_!C^W/'/B'XE7T&ZUT6+^ MSM/9AP;B0?O&'NL?R_\ ;05Z)_PYT\+?]%)US_P!@K[$_9[^!NC_ +.WPMTS MP5HUQ+>P6K22S7LZ*LES*[9+L%XSC:OT44BFSTFBBBF0%%%% 'X^_P#!4SX+ M_P#" ?'*V\8V4'EZ5XLA\R1E&%6\C&)!]67#5\75^^G[3W[-FB?M0?#V/POK M%]/I+P7:7=MJ-K&KRPLN00 W&&!P:^4?^'.GA;_HI.N?^ ,%(M,H?\$C_C9] MKT?Q'\+M0N,R6;?VKI:L>L;$"5!]&VD = 37Z.5\6? __@FCIOP)^*6A^-]% M^(VM3WFFR,6M9;.%4N(F&UXF(Y 8'&17VG3)9\T_MU?M2P_LW_"N2/3)T;QI MKBO;:5#P3#QA[AAZ(#QZL1[U^(]U=37UU-(?B5K44\P6&VLH;.$PVD*_=C3/;DDGN237G7_#G3 MPM_T4G7/_ &"@::1^;GP[\ ZS\4O&^C>%/#]L;K5M4N%MX5 X7/5V]%498GT M!K][?@'\%]&^ /PMT;P;HJ!H[./=(+35[SQ-K=W"+:&[OX8XS:Q9RZH%[L<9/H,5]-T@;N%>^TNL?-;7"@F.5?H>OL37H]%,D_G+\?>!M8^&?C/6/" MOB"V-IJ^E7#6T\9'!(/#+ZJPP0?0U@JS1LKHS(ZD,K*<%2.00?4&OVS_ &IO MV"?"7[3WBC3O$=SK%YX8UJWA^S3W.GPQO]KC!R@<-W7G!]#BO$?^'.GA;_HI M.N?^ ,%(OF/6O^">O[5:_'[X9C0-=NE;QOX=C6&ZW'YKNW&!'<#U/\+>^#WK MZSKXI^"W_!-.T^!/Q(TCQEX=^)VMB^L7^>"2SA$=S$>'B?'\+#\NM?:U,EGX M#?M:_P#)S7Q,_P"PY"DF4J\[7=R,]U>YD93^1%?3-,AA1110(**** /PX_ MX*&?\G@?$#_KK;?^DL5?.=?L+\>?^":.@?';XKZ[XYO/'&K:3R-8Q@MR<[<_C7 ?\ #G3PM_T4G7/_ !@I6+NCV?_ ()F_P#)G_A/_KXO M?_2AZ^IJ\T_9U^"-G^SQ\*=+\#6.J7&LVUA)-(MY=1JDC^9(SG(7CC=BO2Z9 M!^?O_!83_DF'@/\ ["TW_HL5^5U?N]^U?^RKIO[5GAO1-(U+Q!>>'X]+NFND MELX4D,A90N"&Z#BOF?\ X%O\ HI.N?^ ,%(M,\S_X(]?\E=^(7_8#M_\ MTH-?JS7S'^R?^PUH_P"RGXJU[6]-\5:AX@DU:RCLGAO+>.-8PLF_<"O4]J^G M*9+W"F30QW$+Q2HLD4BE71QD,",$$=Q3Z*!'XR?\% OV0W_9_P#'!\3>';5O M^$#UV9FA6,973[@Y+0'T4\E/;([5\CU_19\2_ASH7Q:\#ZOX3\1V:WND:E"8 M94/WE/\ "ZGLRG!![$5\,G_@CIX6RS \@CH:Z&B MF2?B?^UA^P9XP_9WU*[U;1X+GQ/X#9RT.I01EYK1?[EPHY&/[XX/?%?+:L&4 M%2"#W%?THS0I<1/%*BR1N"K(XR&!Z@CN*^7_ (S?\$Y?A!\7;JXU"#3)?"&L MS$L]YH;")68G)9HB-C'\*1:EW/Q/HK]#O$W_ 1Y\0Q7,C>'_B)I\]K_ )J M5BZR'ZE&Q^E<[#_P2'^)4DVV3QAX=BC_ .>GE3-^E*P[H^$ZFLK.XU*\@L[. MWEN[N=@D5O;H7DD8] JCDGZ5^D_@G_@CS#',C^+OB')<1JPQ3L+F/CO]B?_ ()O MS6=Y8>._BW8JKQ%9].\+RX;:PY62Y[9':/\ $^E?I*JK&H55"JHP% P *=13 M)/R0_P""N?\ R7SPM_V O_:QKX;K]K?VJ/V"]&_:D\<:9XDU'Q;J6@2V-E]B M%O9V\4BL-Y;<2W.>:\8_X%O\ HI.N?^ ,%(I-%7_@C?\ \BG\4_\ L)6/ M_HEZ_1>O ?V2OV1M,_9-TOQ-9:;XBO?$*ZY<0W#M>PI&8C&C* -O7.[O7OU, ME[A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N+^+WQ M=\-_ _P/=>+?%=Q-:Z+:ND:?M(?"-OCM\%?%' M@B.XAL[G5+<+;W%PI:.*965T9@.<' KXJ^%OPQUWXP>/-(\(>&[5KK4]1F6 M,;02L*9^:5SV51DD^U?>G@__ (([WIN8V\5_$6$0*";+X:^ O M#_A73A_H6CV,5E$3U(10N3[G&?QKHZ**9 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 )44 %%%% '__9 end EX-101.PRE 4 md-20220217_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 5 md-20220217_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.SCH 6 md-20220217.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document And Entity Information
Feb. 17, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 17, 2022
Entity Registrant Name Mednax, Inc.
Entity Central Index Key 0000893949
Entity Emerging Growth Company false
Entity File Number 001-12111
Entity Incorporation, State or Country Code FL
Entity Tax Identification Number 26-3667538
Entity Address, Address Line One 1301 Concord Terrace
Entity Address, City or Town Sunrise
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33323
City Area Code 954
Local Phone Number 384-0175
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $.01 per share
Trading Symbol MD
Security Exchange Name NYSE
XML 8 md-20220217_htm.xml IDEA: XBRL DOCUMENT 0000893949 2022-02-17 2022-02-17 0000893949 false 8-K 2022-02-17 Mednax, Inc. FL 001-12111 26-3667538 1301 Concord Terrace Sunrise FL 33323 954 384-0175 false false false false Common Stock, par value $.01 per share MD NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports md-20220217.htm md-20220217.xsd md-20220217_lab.xml md-20220217_pre.xml md-ex99_1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "md-20220217.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "md-20220217.htm" ] }, "labelLink": { "local": [ "md-20220217_lab.xml" ] }, "presentationLink": { "local": [ "md-20220217_pre.xml" ] }, "schema": { "local": [ "md-20220217.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "md", "nsuri": "http://www.mednax.com/20220217", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "md-20220217.htm", "contextRef": "C_6c5f45cd-0ec8-465d-8d01-37da35bb59e3", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "md-20220217.htm", "contextRef": "C_6c5f45cd-0ec8-465d-8d01-37da35bb59e3", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0000950170-22-001386-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-001386-xbrl.zip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� 1;[,A@3488#@@/20*!Z M.Z 3N^4X6DG5. ^DC2Q1TJZK]!IF_((PJY)^(M@ZYX=Z$/WJ$K BJ\N*[&Z$ MB'79;=9E&VZ]>U;18G467LAT8.&%X(6T$:O>7HBFR[V&TV6X(2TEVK!7%OP8 M_-@16 ?\V&'Z,;NU]S-R#L*-F4N6 ';_!*:Y#+1A*WBAP_1")_V6U["#(]R0 MEA)]WA3DXS+.2#[B )X##U-TJ8LZ=O,YN+JHHP]-[):/;2!'1XV %-X&W@;> M9@]IQ>ZA[ ,Y=NO$X3OP5UJ@KXU%P%\=FK]R6GY;*Z$:YZY,I$9 "F\#;P-O MLX6]#WCUW]\TW M-)+/89D"@ 6P9@$+\FY.WFVKW<>RR2Y-H4YGT)]R]XSZ\2$P7BT]U;$W &Z^-U\9KX[7QVD_WV@V\^7&^M'OOI=_1S89I^-#+3N:U M%S-^( FP+X M18R2>!1&H>KPS9(QJ]N!_[IH!_XNF1\ _/E>,_#EM]K9L!F$W0"U/&'GP9]% M)@NI/OSCX[?WY]^1+SO?H!$#A&^,\$_"F.63I,AX'&2O 6$3"/^(>1'0C0.S M\'NV,+7DANHIU=!D=#3@19[4YP[7^R6;]. M699$8?#P=B8SM'T'PE0I*SM6'O; MZ+1"W/?W.1DG=[ <6 XLMVN6NQ+1)6CN4&@.@;4^LH#+>6:7X\+EF.AR7-O= MWSG&\"G@,? 8>.QI>,P&CX''] $5/&:4MNO#8XC'P&,:@0H>,TK;]>$QQ&,& M\1AZR1G22^[CK>.F5 'D*)D70":+ LBG/XD*^QKUV^*K.;#:F,WNS\+$YNO& MPI* H^W1X9"4>:9@+M8:(0N'8+@5:",LS_)Z79C2H7"4>99@+M8:(0M_8+@5 M:",LQ^Y9MN/!F,!2 -9D8+5A%-"_0?1_TK?\7L/T$FS)\,.*YB^T+()J$WBC M;-/RSF]G"6E(]X$$%'&5R'(FKF?UW6LCKW+(W(U MD@S4_T@7]Z"X>D!JGN)JP]MNUVK;#1/V4'^H/W@;BGM$BJL-;W=Z5M<%;QNM M_H 4D.H/*4BZ^:*(8UM>TW)8Z+\F&V&0K=B+\?R3AS%+8I;Q2,C^\,,BC((P MOD#R4"N? F#U Q8NNS'K_/C#M6L['HSA8(P!P )8LX %?8.^80S&&H.Y6&N$ M+)08C%Y6#!/HJ!C65CPK*X9A2P?"6QHA"X< AX 0W_C<"O: [-=ZY.FZ,JLB M>!K=,!IT&%\483:9$E@RRQ*(88Y\I28.!I#J 2F\]9Z\-0Q #P, I(!4?TA! MTZ!I&(!1!F BRAIA"L4]>N9V/,MOH\08Z@_>AN)"<8WA;43<9B8PL#E$!^NI MSE+)^36;I%SW^IU0.>P!- YE%@78,U38FWHW)6@-SQ_':8 4P"?:X$LE!A\7O<3[[H] MF(*)*1+L\=BO[;P7=*]1J$Z39SP.&)\FA._?Y0-OM65[3%#74'_L]CCFE\2WE<3:6WY0Y#!ZIM(8\RSPM1GF1AO$% M_2WBN0CJ_$:&W*%6WF8+8(?T*Y$N7M:W::@L2Z*0=."6\D$$>QXE5VL9I)8[-V?RP*WHH^=F6<]YF(-MV*0",PS#&W<2K=M]>S=[^.$ M6]GS5J%&230-8=?&D,Z#/XM,YL,^_./CM_?G;)PF4S:BKX1Q(=-ER4RD*IF6 M,9[G:3@L'0#6L(WOI^U4"[^AFPS1\Z&4G\SW=,WXARAJ<4S[.13K@T16_ MRIJ,2^!I)U^JA),Y.?OSAVK6=T=FBV)$G=4&[?"ZQP, ^4Y>?1OPF*?+!.+P6P=E5&.03 D8A57V!I!GQ628& MF9AQ(@Y1O[/:,5#>^\7=SDV7818.R0GE-X/Z^V?W&SB5C_.\ENMU7DF85M7T M5V-JM>WUU[AM9]TU=JNS]B*[U6O[NQN0W^OI-:#N^O%TUM[F"8?CK+O1O?'L MJ9O8_2Z6-0'HLB]D-:$_!6-OLGVDCNEJ^L*&Q6??L$@ TNWCGU\XWHMGWR:U M80=+,XQB!U'.1N=435(AV">Z9I*Q#X11\&:8OGTO1F(ZI!BR[5A[VQ6W45-+ MX^1^B&TN375,)F[HU@C4/;N<#CR.B1['M=W]]2Z$3P&/@[9LH!D*&] !; E@M@45,USRF M\RV[U[#3)TQ!/U,X>F 1TT%[C0061W)JOQ);[^F(%GLZ'CB0,P[FJ[3ATKZ MU5S? X(=7&Q'9YF "F#8W%)-U[TVG#(=H/* F0Z@^I-O0!EC>" MY>V6UX7U@) J3F0:D,>X'@C.-ZSO!Y('HP$2 V"5!OV ,D;0?(TW%V>5Z^1 M7,Q-XZ"L_GEMHFRY-"5HLGGSJRT'*E$\]5JN*SMS/G[4G9;=7C/L69*%,FDT M2$7$\_!2]GDY<5X_T?B?!^@!TLB'6 1AGCLVMRX"6(,\0!Y0:&"M.=8:(0OR M@$(#:Y.PU@A9D <4&ECKNC0X7\19AK!JL-QHG7"Y?;&SA)1>!*3-BM;Y-"$X M_RY[_I_$(I>-_W-^+?]XZ??;JO[[9:?COL:BNR8L!DCU@-0\EZ -ZSA6M[?+ M#EL:">90M!^0 E+](05';U-H@5TQ1BL_( 6D^D,*BMXBC.[W.M!^D[4?D )2 M_2$%1R.,UE_YGZM>&:F)O5C.USP9_74ZY)F0Z=3I3,39ZC2%8]FV7R8JNFVG M8:("R6[]DJX %MELW5BI;=D.&HD,*A;S$9 M<_L>M-]D[0>D@%1_2,'1>YAT0?GU4'Y "DCUAQ04W9BB^U;7P?8-H[4?D )2 M_2$%1V\11CO8OF%8U@+;-W2PG-]$SL(IW30O#PP.PFR4BERH!(6XE,WJD134 MRK=L >R0?B72QQS M^_TXA^>#S#4S +MW_H((]BX"N!"SM@7!@^QY)U&CU)N&L&MC1N7ASR)@83Q* MID+M^0G"J) ???C]:YE\&]$MPKB0&X:2F4C5=J*,\3Q/PV&1\V$D6)ZP3R*( M^;7%/L:C%I+>FKBQ1I#>ICFWY?J2YH*DD)(V*HC0QLY>ZBD^!""-)>IY5J?? MUTJLB#[@;TR$%/X&_D8#@>KM;VBVN+3VUVNFV!@QG MUV X;A,TY$L'X67]C"#,9A&_&8PC<;W!&\H\6SB^.97)-(F4_-IIEO,T/U/O M<4HCGF8#>6*1_.[*MY[2!U=AD$\&[5:[W7ZU#$-U_T=:>%[W"!QD9"3BQ&YU MNMO9_8ID[ +XWEK"Q&>:8:/])'7"6#IW)S)2,1R,]J3';^VNLUY<5;&F J!)O219.,E0"\ M%R,Q'8J4M1V+N;;KJ)0V_6 ODM(DX.J_.O'8 P:\ALHVP6DEDZW.\=LOK>I+&5@9.U9A:;:>[]AJW[:R[QFYU^^TU%]FM7MO?X8"&::SBK1J!L.JT+.O"A& =/OX MYQ>.]^+9IZ,;5@R;813/$2PVL)EO5R*Z%.Q3&2I^D*'BFV'Z=CE:W-ORPT9U MQ,8)_A KBP^4#M_1O89IB'S#/CU+!X[%1,^5H$ M@-4/6)38-":BGF_UW!Y,X5!,X>B!G4\YW#53#H ,[06P !; :@DL8KKF,5W; M:O<;%D[#%/0SA:,'%C$=M-=(8-'K3/N5V(]EB[.3*,FRU]_M;+;4!*WJB_:= MJ^FG;QH^ZT[/:: M8<^2+)29JT$J(IZ'E[*MS%+W*RV!'B"7?8B5&.8Y='.+,X UR /D 84&UIIC MK1&R( \H-+ V"6N-D 5Y0*&!M?9EYLL05LV=&ZT3+G=+=I:0THN M%G1.I\F M!.??JH:ILP&BL=AB4F[N2*D)[8B^5\S9/17Z?R,&*94IW.1)RM3E5X5M=S MRU2%;[D]IV&J BEO_5*O !8Y;=UXR?$LMVE3 YB"?J8 8 &L6<""O+>8CCF@ M[H,Q! +8,T"%M3=/.[VK9[7ABD*02':G(\K08Y44J3P)0751$P,2U3)+0]^]F2'S+=_TR0^+T M+,^WL9M#%W<$2/6 %+Z]^<2L8_G=AB> 0?WU4'] "DCUAQ0DO8<)&)1?#^4' MI(!4?TA!T8TIVO>MMH\.R4:K/R %I/I#"I+>(H[NX$ KPU(8V,^A@^7\DXCEA,:+;2"Z2@?D?S D,*)-]\R8EN]/NJ1C59_0 I(]8<4)+W-EI&&[5:@ M_'HH/R %I/I#"HK>TV(8#$ / P"D@%1_2$'3H&DS# ;1PXJ9_&;R%DXI9OF M;)PF4Q:$V2@5N5#Y"7%)D&5(!FKE7[8 =DB_$NGB97V;ALJR) H#=EO9((*] MBP A0?,29(?DXN^^"'FM<%W?M^I_"5/]#4T;D:)N^0@I$"+8NPC@A;;9".-X M^HD6/@@^" 0('V2."."#MJD%\[V&;<_@A ["S@#LW@D,(MB[".!#]E"J!@]B M7%;NT?W&J;A/NH] M;M.;VW)]26]!4D@)&Q4\:&-?+_44'P*/YI-7"AUL=Y<=8=?+%6$''(V)D,+A MP.%H(%#-'4ZKL\M-6? V6E C((6W@;>!M]FU1+M]RVYWM1(K_ W\C8F0PM_ MWV@@4+W]C=WJ[_(@:7B;9BD\^E/F>=2/#X'Q:NFIU2:W-6 X6X&Q,+5'P.'8 M3?"0KQV$E_4S@C";1?QF,([$]0;O*%-LX?CF5.;1)%;R:Z=9SM/\3+W)*8UX MF@V&/!/RNRO?>TH?7(5!/AFT6^UV^]4R$-7]]V+CO;5PUF"%L0)&8?:]Z[^# MUCT0Y*Z:>0'L"@&5S]P+,-U-LJ^,;(KL)U ;&U.>JV.R7/\5N^(9*S+YBX01 MB8V*2/XRGU1;(,=C,S$2TZ%(6=NQF&N[CLI%TP]VB\TMD41<_?>(B0BOC=?&:^.U\=IX M;;PV7ANOC==^TB4#Q[WWTM^I2I0O.YG7]\[XA2@78T[YF/ >\.B*WV1EJ>]Q M@:++RZY6_.>8#0Z3*%A^.6<#XWF@;!@ ;@K@/WC$XY%@7R="Y.P_Z#Z1O%<& M,!N >1+&+)\D1<;C('L-")M ^$?,BX!N')B%W[-% N4.B>HIRYW@>)$G=49" M/C>,+P;VF;K\-.(W29$/QN&U",[*-4_'5EA57R!Y1GR6B4$F9EPN'=9OK?(] MY;U?W-U]M]7W/+G&NC(I4XVIY72Z:Z]Q/7?- M-6Z[9=O]-1?9K8ZC]7CVM.%I&@9!)'3/4VF3O[J" M *3;QS^_<%\\>U9WPQVW-1"Z"&9O7GVC?8(JV?1FF+Z]EZ?96_9^H_VWQ@G< MQ$HG@ S".QK"LT%XYMBB;HW!5\2#Q]L;O)%99B+/!KOK_($ _I'^['!!/I ) M[.$*R,"640 6] )Z,4- 9@2JR?&^& 9G(2>;IOXDH:X0IF-]8 MS==&3([EN&VKY^VDK909)F3&W Y)"$TLZ&-\*:H=MU@ETMV&)62P!:36CGSB=3X:T2CR MC*5B),)+N57*8K'(L9*AB5L!I'I "A_=/#%F.U:WNY.NE-!_Z+_)*&N$*13W MZ(G;]1RKWT9%@V'3*F2U-+&?S_E$I&Q4I"FAP[C::H.5"JU<"H#5#UAX[,:, MXSM6I[?#<[QA"@ 6P )8D/=3'!76L[JV!U,P<S>=CG//X(I2] 8DW;$ZG@OU-VO^A)R5 M)N;S>292GH?QA6JX,0YC=19")'@FF#+\TV1\6F0"Z2P=G0V U0]8^/+&9-3Q M+:_3L/X$IJ"?*0!8 &L6L"#OYK4(OM7O-IR(P120SCKRB=@_DR2X"J/(8HDJ M(ZQS6K,TH2E:?J/F9[(7XDRVS(:^G MHZ?: MC;M.:V7%_26I 4LE#6J&A!&T-IV)9Y-T)$U-&\=,CJNJ[E>PVCCF>5 M+X(/N"+3@84K@BO21JQZNZ*VU?:Z5M_K:2A?N"+D7+5GTP9G(?\:\F$8T7VS M>6XUOVEX-#*6RIL$'J--3RT]1'BU\3W;G5=ZB*(Q,4]Q])""3$ F.HK&C&@4 M61E-#&C>H7W&;[AJ;D&Q*1^-TD)0C'H]$W$FD*[1RV$?+K#:F,7N%[ZPFM5\ M-:OO68ZS^[4LC00$E@*PY@.K#:. _@VB?\]M6P[:TIHY$41:8N_V4Q;F!6*8 MHZ6A3GX>D.H!*5SS%H7VMNU9W:9U!K /2P D )2_2$%3V^S(Z:9;P&P^@$+U]V\B2'-L7HV3.%03 ' EBS M@ 5Y-V]BV+?Z-C)71DZ]D+G:N_F4)R!O/=7"\H4>"WAH/&4$^/#WS2L5.SXY M_%UFP]!V2@?C J1P%L<)/IQ%U"!F_O M%E1.N,I>>%B/U<298#WV<,&'MV_,5;U^Q^KT&QXYBO588XT+D,)9'"?XRC?.G[UOR.;C9, MPX=>=C)?RIWQ"U&&"*=\3$HVX-$5O\G*5=WC D67ESU2:\=K/_.$Y,Y9K!M! M]TD$,;^VV,=XU * #0#\(D9)/ JCD.=A$K-D+*%,IH*-TV3*WM%WP[B0[1"K MQHA)/-]+M?PZ.QLO@Y0;H)8G[)(TW?XU2?Z2\CP/_BRR7 3LPS\^?GM_ M_AUYL_,\3\-AH>:1C&ZURNB@#,8HPTD8LWR2%!F/@^PU(&P"X1\Q+P*Z<6 6 M?L\6K93@1=Y4J_=R><2M0SL,W7Y:<1ODB(?C,-K$9Q=A4$^H1$HK*HO MD#PC/LO$(!,S3FPDZK=6BZ3EO5_<+?ZX#+-050[<#.KOKZ@!*1_7Z;1\SW\E M85JUB%F-R6FY3G_=12W7<]=]YB*[U7&=6]<\_3Z)C=9=2\U:-<1/Q_H_@*?M V 1OANG;]V(D MID.1LK9C,==V=U)KOZFL[Z>)C!/ZS@HJX5C@6.!8H,-[U6& O(MZ]XTD0BCJ M!+_6)5#+ZZBCQ;I:LEA7XQNLJSU_?0T\Q5$#JXV][+!D\+YC01W@XX3EV'1[ M>X?'U9AA3&9X_KF^--WC=C<,P :W1T8&Q#4BRYFXGHDX$Y@/:N+E :D>D,(Q M;W$R07._#/779"X.O[P7V_DUR3*6Q$SP-+HAYRR/@2W";#(EL&1E5""&.2)> MK=P+@-4/6'COYN<(=C&K-M6'8U:][UFU6F_/^36;I8FL DMBQ,&:N!- J@>D M\,V-^<5K8V9MGE?&S%H'VWDOZ%ZC:H^1[.;&IPGA^W?YP5;+X A[]9L!HBVL M02) 2-!\L=W;RW0='6+W/,-'K=P3&]+*S:B[*II#<*['W!1M^'2IJ7MN\2'D M:-X+MKM%X=TSR17A!AKO&=C#!J]]F*^M48>R-S\-D^#F[?]Z\],DGT9O_S]0 M2P$"% ,4 " ""-E%4ZY5XR',2 MMP #P @ $ M;60M,C R,C R,3(5 !M9"TR,#(R,#(Q-U]L M86(N>&UL4$L! A0#% @ @C915(93@P&%! 0B4 !, M ( !KAL &UD+3(P,C(P,C$W7W!R92YX;6Q02P$"% ,4 " ""-E%4@JWM M(E-' :8P@ #0 @ %D( ;60M97@Y.5\Q+FAT;5!+!08 1 !0 % #